Shots:
Revolution Medicines has started treatment in global P-III (RASolute 303) trial assessing daraxonrasib (PO) as monotx. & in combination with CT for the treatment of pts with previously untreated metastatic PDAC, irrespective of tumor RAS genotype
The trial will assess PFS & OS as 1EP, while the key 2EPs include additional measures of antitumor…
